US EditionBrain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer
- In recognition of a day dedicated to raising awareness about DIPG, an award of $68,000 has been granted to support a clinical trial developing a vaccine aimed at treating aggressive childhood brain tumors.
- This funding addresses the urgent need caused by DIPG's low survival rates and limited treatment options including radiation and chemotherapy.
- Drs. Narendran and Sipila, based at Alberta Children’s Hospital and the University of Calgary, are leading a study evaluating a neoantigen-based vaccine aimed at stimulating the immune system to target tumors.
- Fewer than 10% of children survive two years after diagnosis, and the work aims to improve outcomes and offer renewed hope through innovative immunotherapy.
- Brain Cancer Canada continues investing in pioneering research and acknowledges grassroots efforts that enable progress in treatments for aggressive brain tumors like DIPG.
Insights by Ground AI
Does this summary seem wrong?
16 Articles
16 Articles
All
Left
13
Center
1
Right
1
The Globe & Mail+15 Reposted by 15 other sources
Brain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
·Canada
Read Full ArticleCoverage Details
Total News Sources16
Leaning Left13Leaning Right1Center1Last UpdatedBias Distribution87% Left
Bias Distribution
- 87% of the sources lean Left
87% Left
L 87%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
